Spinal Cord Injury and Haematopoietic stem-cell transplantation (HSCT): what the trial registry contains

Why this is studied in Spinal Cord Injury

Traumatic spinal cord injury combines the initial mechanical lesion with secondary inflammation, cavity formation and glial scarring. Cell strategies aim to bridge or protect rather than regrow a cord. Timing splits the field sharply: acute neuroprotection and chronic reconstruction are different scientific problems with different evidence.

What HSCT means in this table

Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.

The numbers

Every figure below comes from one reproducible query (spinal cord injury x hematopoietic stem cell transplantation) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

Evidence here is mid-maturity: a handful of Phase 3 or 4 registrations (1 of 11) sit above a much larger early-phase base.

Completion status: 3 completed, 2 stopped early (18% of all records). A registration is a plan, not a result.

Median planned enrolment is 30 participants (largest single study: 60). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

7 countries host at least one site. Brazil is the largest single contributor at roughly 25% of country mentions in this sample.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Sponsorship leans commercial: 3 of the most frequent lead sponsors read as academic or hospital entities and 4 as companies. Who pays shapes what gets measured and what gets published.

• Hospital Sao Rafael — 2 records
• SENAI CIMATEC — 1 record
• The First Affiliated Hospital of Dalian Medical University — 1 record
• China Spinal Cord Injury Network — 1 record
• Pharmicell Co., Ltd. — 1 record
• Federal Research Clinical Center of Federal Medical & Biological Agency, Russia — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many HSCT studies for Spinal Cord Injury are recruiting right now?

0 of 11 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is HSCT an approved treatment for Spinal Cord Injury?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 11 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on HSCT for Spinal Cord Injury?

1 of 11 records carry a Phase 3 or Phase 4 label and 3 are marked completed. Registrations run from 2008 to 2023.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.